Pathogen Panel Testing AHS – G2149

Description of Procedure or Service

Description
Infectious diseases can be caused by a wide range of pathogens. Conventional diagnostic methods like culture, microscopy with or without stains and immunofluorescence, and immunoassay often lack sensitivity and specificity and have long turnaround times. Panels for pathogens using multiplex amplified probe techniques and multiplex reverse transcription can detect and identify multiple pathogens in one test using a single sample (Palavecino, 2015).

Related Policies
Diagnosis Of Vaginitis Including Multi-Target PCR Testing AHS – M2057
Identification Of Microorganisms Using Nucleic Acid Probes AHS- M2097
Onychomycosis Testing AHS – M2172

***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.

Policy
BCBSNC will provide coverage for pathogen panel testing when it is determined the medical criteria or reimbursement guidelines below are met.

Note: The coverage criteria outlined in this policy are not applicable to diagnostic COVID-19 testing.

Benefits Application
This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

When Pathogen Panel Testing is covered
1. Reimbursement is allowed for multiplex PCR-based panel testing of gastrointestinal pathogens (GIP) up to 5 pathogens in any of the following situations* (See Note 1):
   a. Community-acquired diarrhea of ≥7 days duration; or
   b. Diarrhea with signs or risk factors for severe disease (fever, bloody diarrhea, dysentery, dehydration, severe abdominal pain, hospitalization and/or immunocompromised state).

2. In the outpatient setting, reimbursement is allowed for multiplex PCR-based panel testing of gastrointestinal pathogens up to 11 pathogens in immunosuppressed or HIV positive patients AND any of the following situations* (See Note 1):
   a. Community-acquired diarrhea of ≥ days duration; or
   b. Diarrhea with signs or risk factors for severe disease (fever, bloody diarrhea, dysentery, dehydration, severe abdominal pain, hospitalization and/or immunocompromised state).

3. Reimbursement is allowed for multiplex PCR-based panel testing of up to 5 respiratory pathogens for patients displaying signs and symptoms of a respiratory tract infection, as evidenced by a compatible clinical syndrome including at least one of the following: temperature of 102 or greater, pronounced dyspnea, tachypnea, or tachycardia.

Note 1: According to CMS LCD L37766, “A GIP test panel is a single service with a single unit of service (UOS=1). A panel cannot be unbundled and billed as individual components regardless of the fact that the GIP test reports multiple individual pathogens and/or targets. The panel is a closed system performed on a single platform, and as such, is a single test panel with multiple component (UOS=1). If *C. difficile* is not included in a GIP panel, testing for *C. difficile* may be reasonable and necessary when ordered in addition to a GIP bacterial pathogen panel and supported by documentation in the medical record. (CMS, 2019).”

**When Pathogen Panel Testing is not covered**

1. In the outpatient setting, reimbursement is not allowed for multiplex PCR-based panel testing of 12 or MORE gastrointestinal pathogens.

2. In the outpatient setting, reimbursement is not allowed for multiplex PCR-based panel testing of 6 or MORE respiratory pathogens.

3. In the outpatient setting, reimbursement is not allowed for multiplex PCR-based panel testing of pathogens in CSF.

4. In the outpatient setting, reimbursement is not allowed for molecular detection-based panel testing of blood stream pathogens.

5. Reimbursement is not allowed for the use of molecular-based panel testing for general screening of microorganisms. These tests include, but are not limited to the following:
   a. Molecular-based panel testing on stool samples, such as SmartGut™
   b. Molecular-based panel testing on vaginal swabs, such as SmartJane™
   c. Molecular-based panel testing on urine samples, such as UroSwab®

6. Reimbursement is not allowed for the molecular detection-based panel testing of urine pathogens for the diagnosis of urinary tract infections.

7. In the outpatient setting, reimbursement is not allowed for using molecular-based panel testing to screen for or diagnose wound infections (i.e. skin/soft tissue infections), including diagnostic testing to confirm biofilm presence.
Policy Guidelines

Background
There has been a move in recent years towards employing molecular tests that use multiplex polymerase chain reaction (PCR) to simultaneously detect multiple pathogens associated with an infectious disease rather than one particular organism. These tests are usually offered as a panel for a particular infectious condition, such as sepsis and blood stream infections, central nervous system infections (for example, meningitis and encephalitis), respiratory tract infections, urinary tract infections or gastrointestinal infections. These assays are often more sensitive than conventional culture-based or antigen detection. The high diagnostic yield is particularly important when clinical samples are difficult to collect or are limited in volume (e.g., CSF). Multiplex PCR assays are also particularly beneficial when different pathogens can cause the same clinical presentation, thus making it difficult to narrow down the causative pathogen. Access to comprehensive and rapid diagnostic results may lead to more effective early treatment and infection-control measures. Disadvantages of multiplex PCR assays include high cost of testing and potential false negative results due to preferential amplification of one target over another (Palavecino, 2015).

The Centers for Medicare and Medicaid Services (CMS, 2019) report that the top target pathogens causing infections include 

- *Salmonella*,
- *Campylobacter*,
- *Shigella*,
- *Cryptosporidium*,
- Shiga toxin producing *E. coli* non-O157 and Shiga toxin producing *E. coli* O157; these pathogens “represent the top 90-95% of foodborne infections [incidence of infection per 100,000 population].”

Gastrointestinal Pathogen Panel

Approximately 2 billion cases of diarrheal disease occur worldwide every year, resulting in 1.9 million deaths in children younger than five years of age annually (Farthing et al., 2013). The Centers for Disease Control and Prevention has estimated that nearly 48 million cases of acute diarrheal infection occur annually in the United States, at an estimated cost upwards of $150 billion (Scallan, Griffin, Angulo, Tauxe, & Hoekstra, 2011). Approximately 31 major pathogens acquired in the United States caused an estimated 9.4 million episodes of diarrheal illness, 55,961 hospitalizations, and 1,351 deaths each year. Additionally, unspecified agents caused approximately 38 million episodes of foodborne illnesses and resulted in 71,878 hospitalizations and 1,686 deaths. Diarrhea can be classified as acute (lasting less than 14 days), persistent (14 and 30 days), and chronic (lasting for greater than a month) (Riddle, DuPont, & Connor, 2016). Further, healthcare and antibiotic associated diarrhea are mainly caused by toxin-producing *Clostridium difficile* causing more than 300,000 cases annually (CMS, 2019).

Acute infectious gastroenteritis is generally associated with other clinical features like fever, nausea, vomiting, severe abdominal pain and cramps, flatulence, bloody stools, tenesmus, and fecal urgency. A wide spectrum of enteric pathogens can cause infectious gastroenteritis, including bacteria such as *Campylobacter*, *Clostridium difficile*, *Salmonella*, *Shigella*, *Vibrio* and *Yersinia*; viruses, such as Norovirus, Rotavirus, Astroviurs and Adenovirus; and parasites, such as *Giardia*, *Entamoeba histolytica* and *Cryptosporidium* (Riddle et al., 2016).

Stool culture is the primary diagnostic tool for a suspected bacterial infection, but it is time-consuming and labor intensive. Stool samples are collected and analyzed for various bacteria present in the lower digestive tract via cell culture; these bacteria may be normal or pathogenic (Humphries & Linscott, 2015). By identifying the type of bacteria present in a stool sample, a physician will be able to determine if the bacteria are causing gastrointestinal problems in an individual. However, stool culture has a low positive yield. Similarly, methods like electron microscopic examination and immunoassay that are used to diagnose viruses are labor intensive and need significant expertise (Zhang, Morrison, & Tang, 2015). Multiplex PCR-based assays have shown superior sensitivity to conventional methods for detection of enteric pathogens and are increasingly used in the diagnosis of infectious gastroenteritis. These assays have significantly improved workflow and diagnostic output in the diagnosis of gastrointestinal infections (Zhang et
Several FDA-approved multiplex PCR assays are now commercially available. Some assays can detect only bacterial pathogens in stool, whereas others can detect bacterial, viral, and parasitic pathogens. The Strong-LAMP assay is a new technique which uses PCR to detect Strongyloides in stool and urine samples (Fernandez-Soto et al., 2016), although it is not yet widely available (La Hoz & Morris, 2019).

Several proprietary panels for the assessment of gastrointestinal pathogens are available. BioFire Diagnostics offers an FDA-approved 22-target testing panel for the gastroenteritis, termed the BioFire FilmArray Gastrointestinal Panel. The panel’s targets include bacteria (Campylobacter, Clostridium difficile, Plesiomonas shigelloides, Salmonella, Yersinia enterocolitica, Vibrio (parahaemolyticus, vulnificus), Vibrio cholerae, Enteropathogenic E. coli, Enterotoxigenic E. coli, Shiga-like toxin-producing E. coli stx1/stx2, E. coli O157 and Shigella/Enteroinvasive E. coli), parasites (Cryptosporidium, Cyclospora cayetanensis, Entamoeba histolytica and Giardia lamblia), and viruses (Adenovirus F40/41, Astrovirus, Norovirus GI/GII, Rotavirus A and Sapovirus (I, II, IV, and V)) (BioFire, 2019a). The manufacturer claims a sensitivity of 98.5% and specificity of 99.2% for this test and states that results are available within one hour of testing. However, BioFire notes that the test has not been evaluated for immunocompromised patients (BioFire, 2019a).

The FDA-approved xTAG Gastrointestinal Pathogen Panel, developed by Luminex, can simultaneously identify multiple bacterial, viral and parasitic nucleic acids in both fresh and frozen human stool samples. This test can provide results in as little as five hours, and can “Detect and identify >90% of the causative bacterial, viral, and parasitic agents of gastroenteritis in the same day (Luminex, 2020b).” The xTAG Gastrointestinal Pathogen Panel is able to identify Campylobacter, Clostridium difficile, Toxin A/B, Escherichia coli O157, Enterotoxigenic E. coli (ETEC) LT/ST, Shiga-like Toxin producing E.coli (STEC) stx1/stx2, Salmonella, Shigella, Vibrio cholerae, Yersinia enterocolitica, Adenovirus 40/41, Norovirus GI/GII, Rotavirus A, Cryptosporidium, Entamoeba histolytica, and Giardia.

The Biocode Gastrointestinal Pathogen Panel is also FDA approved and it uses a 96-well microplate to simultaneously detect 17 diarrhea causing pathogens (Campylobacter, Clostridium difficile toxins A and B, E. coli O157, Enterotoxigenic E. coli LT/ST (ETEC), Salmonella, Shiga-like toxin producing E. coli stx1/stx2, Shigella/ Enteroinvasive E. coli, Vibrio/ Vibrio parahemolyticus, Yersinia enterocolitica, Adenovirus 40/41, Norovirus GI/GII, Rotavirus A, Cryptosporidium, Entamoeba histolytica, and Giardia lamblia) in stool samples (BioCode, 2020a). This rapid multiplex screening assay is low cost and may be helpful with infection control.

Respiratory Pathogen Panel

Upper respiratory tract infections (involving the nose, sinuses, larynx, pharynx and large airways) can be caused by a variety of viruses and bacteria. These infections may lead to several different patient ailments such as the common cold, acute bronchitis, influenza and respiratory distress syndromes. Regarding the common cold, the most common virus is rhinovirus; the bacteria that most commonly causes a sore throat (pharyngitis) is Streptococcus pyogenes (Thomas & Bomar, 2020). Lower respiratory tract infections occur in the lungs and any airways below the larynx. Lower respiratory infections include pneumonia, bronchitis, tuberculosis and bronchiolitis (Hansen, Lykkegaard, Thomasen, & Hansen, 2020). The CDC (2019a) has stated that in travelers, viral pathogens are the most common cause of respiratory infections; “causative agents include rhinoviruses, respiratory syncytial virus, influenza virus, parainfluenza virus, human metapneumovirus, measles, mumps, adenovirus, and coronaviruses (CDC, 2019a).” Further, in travelers, bacterial pathogens are less common but include Chlamydophila pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae and Mycoplasma pneumoniae.

Traditional methods used for the diagnosis of viral respiratory tract infections are direct antigen testing (non-immunofluorescent and immunofluorescent methods) and conventional and rapid cell culture (Ginocchio, 2007). These tests have several limitations including a slow turnaround time,
low sensitivity, and labor-intensive processes. Acute respiratory infections may also be diagnosed by a simple respiratory exam, i.e. the physician focuses on the patient’s breathing and checks for fluid and inflammation in the lungs. Symptoms of a respiratory tract infection may include a stuffed nose, cough, fever, sore throat, headache, and difficulty breathing. Chest X-rays may be used to check for pneumonia, and blood/mucus samples may be used to confirm the presence of certain bacteria and/or viruses via cell culture. The doctor may also check the ears, nose and throat. Treatment typically incorporates over the counter medications, rest, fluids and antibiotics (if a bacterial infection is identified).

Considerable progress has been made in the development of molecular methods to detect multiple respiratory pathogens simultaneously. Molecular detection, including multiplex PCR assays, is currently the gold standard for viral respiratory diagnosis (Bonnin et al., 2016). Multiplex PCR-based assays are now commercially available to detect several viral pathogens like adenovirus, influenza A and respiratory syncytial virus as well as bacterial pathogens like Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila. These tests are rapid, sensitive, specific, and the preferred testing method to identify most respiratory pathogens (Caliendo, 2011; Pammi, 2019; Yan, Zhang, & Tang, 2011). These tests may be a more reliable diagnostic test as they can be performed in just hours, do not require as large a volume of blood, and are not affected by antepartum antibiotics (Pammi, 2019).

BioFire has released two FDA approved respiratory panel tests, the FilmArray RP and RP2. The new test, RP2, has added Bordetella parapertussis as a target compared to the previous version of the respiratory panel (BioFire, 2019b). The original version is able to detect 17 viral (Adenovirus, Coronavirus HKU1, Coronavirus NL63, Coronavirus 229E, Coronavirus OC43, Human Metapneumovirus, Human Rhinovirus/Enterovirus, Influenza A H1, Influenza A H3, Influenza A H1-2009, Influenza B, Parainfluenza Virus 1, Parainfluenza Virus 2, Parainfluenza Virus 3, Parainfluenza Virus 4, Respiratory Syncytial Virus) and 3 bacterial (Bordetella pertussis, Chlamydia pneumoniae and Mycoplasma pneumoniae) targets in one hour with a 97.1% sensitivity and 99.3% specificity (BioFire, 2019b).

GenMark Diagnostics has developed the FDA-approved rapid ePlex® Respiratory Pathogen Panel test which can identify the most common bacterial and viral pathogens causing upper respiratory infections (including Adenovirus, Coronavirus (229E, HKU1, NL63, OC43), Human Metapneumovirus, Human Rhinovirus/Enterovirus, Influenza A, Influenza A H1, Influenza A H3, Influenza H3, Influenza B, Parainfluenza 1, Parainfluenza 2, Parainfluenza 3, Parainfluenza 4, Respiratory Syncytial Virus A, Respiratory Syncytial Virus B, Chlamydia pneumoniae and Mycoplasma pneumoniae) (GenMark, 2017). The ePlex Respiratory Pathogen Panel test was more efficient than a laboratory developed PCR assay resulting “in a significant decrease in time to result, enabling a reduction in isolation days in half of the patients,” and increasing the identification of the causative pathogen (van Rijn et al., 2018).

The BioCode Respiratory Pathogen Panel is the FDA approved low-cost test that can simultaneously detect respiratory pathogens in nasopharyngeal swabs. This test is designed in a 96-well microplate format. The following 14 pathogens can be identified with this panel: Adenovirus, Coronavirus (229E, OC43, HKU1, and NL63), Human Metapneumovirus A/B, Influenza A, including subtypes H1, H1 2009 Pandemic, and H3, Influenza B, Parainfluenza 1, Parainfluenza 2, Parainfluenza 3, Parainfluenza 4, Respiratory Syncytial Virus A/B, Rhinovirus/Enterovirus, Bordetella pertussis, Chlamydia pneumoniae and Mycoplasma pneumoniae (BioCode, 2020b).

The NxTAG Respiratory Pathogen Panel, developed by Luminex, is able to simultaneously detect 20 pathogens (Influenza A, Influenza A H1, Influenza A H3, Respiratory Syncytial Virus A, Respiratory Syncytial Virus B, Rhinovirus/Enterovirus, Parainfluenza virus 1, Parainfluenza virus 2, Parainfluenza virus 3, Parainfluenza virus 4, Human Metapneumovirus, Adenovirus, Coronavirus HKU1, Coronavirus NL63, Coronavirus 229E, Coronavirus OC43, Human Bocavirus, Chlamydia pneumoniae and Mycoplasma pneumoniae) in a single test (Luminex, 2020a).
Pathogen Panel Testing AHS – G2149

Central Nervous System Pathogen Panel

The brain is well protected from microbial invasion via the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB). Nonetheless, bacteria, fungi, viruses and amoebae do infect the brain and the consequences are often fatal. Points of entry include the BBB, BCSFB, and the olfactory and trigeminal nerves (Dando et al., 2014). Meningitis, which is when the brain and/or spinal cord become inflamed, is typically caused by viral infections due to enteroviruses; other neurotropic viruses include herpes simplex viruses, human cytomegalovirus, varicella-zoster virus, and rabies virus (Dando et al., 2014). Bacterial meningitis is most commonly caused by Streptococcus pneumoniae, followed by Streptococcus agalactiae; in children, Neisseria meningitidis is most likely to cause meningitis (Dando et al., 2014). Fungal meningoencephalitis, which is described as inflammation of the brain and surrounding membranes, is often caused by the yeast Cryptococcus neoformans; further, meningococcal meningitis is typically caused by Neisseria meningitidis (Dando et al., 2014). Many other types of pathogens may enter the central nervous system. The increasing use of molecular tests for the detection of pathogens in cerebrospinal fluid (CSF) has redefined the diagnosis and management of central nervous system (CNS) infections such as meningitis and encephalitis. However, it is important that test results correlate to the probability of infection. According to Petti, the number of false-positive test results increase when the multiplex PCR tests are ordered in the absence of an elevated leukocyte count or elevated protein level in the CSF. Hence, the predictive value of the test increases when the tests are ordered only for those patients with a moderate to high pretest probability of having CNS infections based on clinical presentation and CSF findings (Petti, 2019).

The evaluation of meningitis routinely includes molecular testing, particularly when the patient is suspected to have viral meningitis. Although use of Gram stain and culture is the gold standard for diagnosis of bacterial meningitis, multiplex PCR assays may be useful as an adjunct, especially in patients who have already received antibiotic treatment. Other lab findings (for example, CSF cell count, glucose, and protein analyses) should be used as a screening method prior to the performance of molecular testing. Molecular assays for meningitis caused by fungi, parasites, rickettsia, and spirochetes are in development at this time (Petti, 2019).

Similarly, molecular testing of CSF is recommended when viral encephalitis, especially encephalitis due to Herpesviridae, is suspected. For other viral encephalitis, the clinical sensitivity and predictive value of multiplex-PCR assays is unknown. Therefore, a negative result does not exclude infection, and a combined diagnostic approach, including other methods like serology, may be necessary to confirm the diagnosis. Multiplex PCR-based assays may be useful in certain cases of bacterial meningitis, especially when a slow-growing or uncultivable bacterium like Coxiella burnetti is involved. Molecular assays for encephalitis caused by fungi, parasites, rickettsia, and spirochetes need to be investigated further and are not routinely available at this time (Petti, 2019).

The FDA approved BioFire FilmArray meningitis/encephalitis panel can provide information on 14 different pathogens in one hour. This test uses 0.2 mL of cerebrospinal fluid, and is able to detect bacteria (Escherichia coli K1, Haemophilus influenzae, Listeria monocytogenes, Neisseria meningitidis, Streptococcus agalactiae, and Streptococcus pneumoniae), viruses (Cytomegalovirus, Enterovirus, Herpes simplex virus 1, Herpes simplex virus 2, Human herpesvirus 6, Human parechovirus, and Varicella zoster virus) and yeast (Cryptococcus neoformans/gattii) (BioFire, 2020b). BioFire states that this panel has an overall sensitivity of 94.2% and a specificity of 99.8%.

Sepsis Panel

Sepsis, also known as blood poisoning, is the body’s systemic immunological response to an infection. Sepsis occurs when an infection (in the lungs, skin, urinary tract or another area of the body) triggers a chain reaction in an individual (CDC, 2019c). Sepsis can lead to end-stage organ failure and death. Septic shock occurs when sepsis results in extremely low blood pressure and abnormalities in cellular metabolism. The annual incidence of severe sepsis and septic shock in the
Pathogen Panel Testing AHS – G2149

United States is 300 per 100,000 people; sepsis is “the most expensive healthcare problem in the United States” (Gyawali, Ramakrishna, & Dhamoon, 2019).

Sepsis-related mortality remains high, and inappropriate antimicrobial and anti-fungal treatment is a major factor contributing to increased mortality (Liesenfeld, Lehman, Hunfeld, & Kost, 2014). Blood culture is the standard of care for detecting bloodstream infections, but the method has several limitations. Fastidious, slow-growing, and uncultivable organisms are difficult to detect by blood culture, and the test sensitivity decreases greatly when antibiotics have been given prior to culture. Additionally, culture and susceptibility testing may require up to 72 hours to produce results. Multiplex PCR assays of positive blood culture bottles have a more rapid turnaround time and are not affected by the administration of antibiotics. Faster identification and resistance characterization of pathogens may lead to earlier administration of the appropriate antibiotic, resulting in better outcomes, and may lessen the emergence of antibiotic-resistant organisms (Banerjee et al., 2015).

The T2Bacteria Panel is the first “FDA-cleared test to identify sepsis-causing bacteria directly from whole blood without the wait for blood culture (T2Biosystems, 2019).” This panel is able to identify 50% of all bloodstream infections, 90% of all ESKAPE bacteria (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Escherichia coli) pathogens, and 70% of all blood culture species identified in the emergency room with a 95% sensitivity and 98% specificity (T2Biosystems, 2019).

The Magicplex™ Sepsis Real-time Test by Seegene is able to identify more than 90 sepsis-causing pathogens with only 1 mL of whole blood. This test identifies both bacteria and fungi, as well as three drug resistance markers in only six hours (Seegene, 2020).

GenMark has developed three ePlex® Blood Culture Identification (BCID) Panels. These include the ePlex BCID-Gram Positive Panel (identifies 20-gram positive bacteria and four resistance genes), the ePlex BCID-Gram Negative Panel (identifies 21-gram negative bacteria and six resistance genes), and the ePlex BCID-Fungal Panel (identifies 15-fungal organisms) (GenMark, 2020).

BioFire has developed the FilmArray Blood Culture Identification Panel which can identify 24 gram-positive bacteria (Enterococcus, Listeria monocytogenes, Staphylococcus, Staphylococcus aureus, Streptococcus, Streptococcus agalactiae, Streptococcus pneumoniae, and Streptococcus pyogenes), gram-negative bacteria (Acinetobacter baumannii, Haemophilus influenzae, Neisseria meningitidis, Pseudomonas aeruginosa, Enterobacteriaceae, Enterobacter cloacae complex, Escherichia coli, Klebsiella pneumoniae, Proteus, and Serratia marcescens) and yeast (Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, and Candida tropicalis) pathogens (BioFire, 2020a).

Urinary Tract Infection Panel

Urinary tract infections (UTIs) occur in the urinary system and can be either symptomatic or asymptomatic. UTIs can include cystitis, an infection of the bladder or lower urinary tract, pyelonephritis, an infection of the upper urinary tract or kidney, urosepsis, urethritis, and male-specific conditions, such as bacterial prostatitis and epididymitis (Bonkat et al., 2020; Hooton & Gupta, 2019). Typically, in an infected person, bacteriuria and pyuria (the presence of pus in the urine) are present and can be present in both symptomatic and asymptomatic UTIs. A urine culture can be performed to determine the presence of bacteria and to characterize the bacterial infection (Meyrier, 2019).

Panels comprising common UTI pathogens are now commercially available. Firms such as MicroGenDX and NovaDX offer panels consisting of many different pathogens involved in UTIs, such as Pseudomonas aeruginosa (MicroGenDX, 2019a; NovaDX, 2019). The NovaDX is a qPCR based test which can detect 17 pathogens including bacteria (Acinetobacter baumannii, Citrobacter
Pathogen Panel Testing AHS – G2149

freundii, Enterobacter aerogenes, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Pseudomonas aeruginosa, Staphylococcus saprophyticus, and Streptococcus agalactiae) and yeast (Candida albicans) (NovaDX, 2019).

Cardwell, Crandon, Nicolau, McClure, and Nailor (2016) evaluated the microbiology of UTIs in hospitalized adults. Approximately 308 patients were included, with a total of 216 identified pathogens. The authors separated patients into three groups; “community acquired (Group 1); recent healthcare exposure (Group 2); or a history of identification of an extended-spectrum beta lactamase (ESBL)-producing organism (Group 3).” Escherichia coli was found to be the most common pathogen, but the frequency differed between groups. Other commonly identified pathogens included Pseudomonas aeruginosa (Cardwell et al., 2016).

Medina and Castillo-Pino (2019) estimated the prevalence of certain pathogens in UTI (complicated or uncomplicated). The authors found that up to 75% of uncomplicated UTIs and up to 65% of complicated are caused by uropathogenic Escherichia coli (UPEC). Other commonly seen pathogens included Enterococcus spp, Group B Streptococcus, K. pneumonia, and S. saprophyticus (Medina & Castillo-Pino, 2019).

Wound Panel

Wounds (acute or chronic) are almost always colonized by microbes, thereby leading to a significant rate of infection. Panel testing many pathogens have been proposed as a method to quickly identify and therefore treat a wound infection (Armstrong, 2019). These panels may be culture-based or nucleic acid-based; nucleic acid panels are typically touted for their speed compared to culture panels.

Firms, such as GenetWorx, Viracor, and MicroGenDX, offer comprehensive panels addressing many different common pathogens, resistance genes, and more. Genera, such as Streptococcus, Enterococcus, and Staphylococcus, are frequent targets of these panels, and many different combinations of panels are available (GenetWorx, 2019; MicroGenDX, 2019b; Viracor, 2019).

The Wounds Pathogen Panel by GenetWorx is able to identify 22 targets including bacteria, fungi, and viruses. Targeted pathogens include Enterococcus faecalis, Methicillin Resistant Staphylococcus aureus (MRSA), Methicillin Sensitive Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Streptococcus pyogenes (Group A Strep), Streptococcus agalactiae (Group B Strep), Streptococcus dysgalactiae (Group C Strep), Bacteroides fragilis, Bartonella henselae, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Bartonella Quintana, Candida albicans, Candida glabrata, Candida parapsilosis, Candida dubliniensis, Candida tropicalis, Mycobacterium fortuitum, Herpes Simplex Virus 1, Herpes Simplex Virus 2 and Herpes Simplex Virus 3 (GenetWorx, 2019).

The Viracor Skin and Soft Tissue Infection Panel can identify 19 bacterial targets using TEM-PCRTM (Target Enriched Multiplex Polymerase Chain Reaction). These bacterial targets include Acinetobacter baumanii, Bacteroides spp., Citrobacter freundii, Clostridium novyi/septicum, Clostridium perfringens, Enterobacter aerogenes, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Kingella kingae, Klebsiella spp., Morganella morganii, Proteus mirabilis, Proteus vulgaris, Staphylococcus aureus, MRSA - Meth. resistant S. aureus, Panton-Valentine leukocidin gene, Staphylococcus lugdunensis, Streptococcus pyogenes (Group A) and Pseudomonas aeruginosa (Viracor, 2019). This test has not been approved by the FDA and has a 2-3 day turnaround time.

Ray, Suaya, and Baxter (2013) described the incidence and microbiology of skin and soft tissue infections (SSTIs). The authors focused on members of a Northern California health plan, identifying 376262 patients with 471550 SSTIs. Approximately 23% of these infections were cultured, 54% of these cultures were pathogen-positive, and Staphylococcus aureus was found in
81% of these specimens. The researchers calculated the rate of diagnosed SSTIs to be 496 per 10000 person-years (Ray et al., 2013).

A comprehensive list of the main commercial pathogen panel tests mentioned above can also be found in the table below. This table was last updated on 2/11/2020.

<table>
<thead>
<tr>
<th>Type of Panel</th>
<th>Name</th>
<th>Pathogens Identified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal</td>
<td>BioFire FilmArray Gastrointestinal Panel</td>
<td>22 targets including bacteria, parasites and viruses</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Luminex xTAG Gastrointestinal Pathogen Panel</td>
<td>19 targets including bacteria, parasites and viruses</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Biocode Gastrointestinal Pathogen Panel</td>
<td>17 targets including bacteria, parasites and viruses</td>
</tr>
<tr>
<td>Respiratory</td>
<td>BioFire FilmArray Respiratory 2 (RP2) Panel</td>
<td>21 targets including viruses and bacteria</td>
</tr>
<tr>
<td>Respiratory</td>
<td>BioFire FilmArray Respiratory (RP) Panel</td>
<td>17 targets including viruses and bacteria</td>
</tr>
<tr>
<td>Respiratory</td>
<td>GenMark Diagnostics Rapid ePlex® Respiratory Pathogen Panel</td>
<td>17+ targets including viruses and bacteria</td>
</tr>
<tr>
<td>Respiratory</td>
<td>BioCode Respiratory Pathogen Panel</td>
<td>14 targets including viruses and bacteria</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Luminex NxTAG Respiratory Pathogen Panel</td>
<td>20 targets including viruses and bacteria</td>
</tr>
<tr>
<td>Central Nervous System</td>
<td>BioFire FilmArray Meningitis/Encephalitis Panel</td>
<td>14 targets including bacteria, viruses and yeast</td>
</tr>
<tr>
<td>Sepsis</td>
<td>T2Bacteria Panel</td>
<td>5 ESKAPE pathogens and potentially more targets</td>
</tr>
<tr>
<td>Sepsis</td>
<td>Magicplex™ Sepsis Real-time Test</td>
<td>90+ including bacteria and fungi</td>
</tr>
<tr>
<td>Sepsis</td>
<td>GenMark ePlex® Blood Culture Identification Panel (Gram-positive, Gram-negative and fungal)</td>
<td>Collectively identify 56 bacteria and fungi</td>
</tr>
<tr>
<td>Sepsis</td>
<td>BioFire Blood Culture</td>
<td>24 targets including bacteria and yeast</td>
</tr>
<tr>
<td>Urinary Tract Infection</td>
<td>NovaDX UTI Test</td>
<td>17 targets including bacteria and yeast</td>
</tr>
<tr>
<td>Wound</td>
<td>GenetWorx Wounds Pathogen Panel</td>
<td>22 targets including bacteria, fungi and viruses</td>
</tr>
<tr>
<td>Wound</td>
<td>Viracor Skin and Soft Tissue Infection Panel</td>
<td>19 bacterial targets</td>
</tr>
</tbody>
</table>

**Clinical Validity and Utility**

Several studies demonstrated the overall high sensitivity and specificity of the gastroenterology pathogen panels (Buss et al., 2015; Claas, Burnham, Mazzulli, Templeton, & Topin, 2013; Onori et al., 2014). Several studies have also indicated that gastrointestinal pathogen panels are more sensitive than culture, microscopy, or antigen detection, thus illustrating the potential of panels as a
diagnostic tool for gastrointestinal infections (Buss et al., 2015; Couturier, Lee, Zelyas, & Chui, 2011; Humphrey et al., 2016; Liu et al., 2014; Operario & Houpt, 2011). Zhang and colleagues concluded that using multiplex PCR assays in the work-up of infectious gastroenteritis has the potential to improve the diagnosis (Zhang et al., 2015).

Yoo et al. (2019) compared the Seegene Allplex Gastrointestinal, Luminex xTAG Gastrointestinal Pathogen Panel, and BD MAX Enteric Assays in an effort to determine which was the most efficient in detecting gastrointestinal pathogens from clinical stool samples. A total of 858 stool samples were used in this study. “The overall positive percentage agreements of Seegene, Luminex, and BD MAX were 94% (258 of 275), 92% (254 of 275), and 78% (46 of 59), respectively. For Salmonella, Luminex showed low negative percentage agreement because of frequent false positives (n = 31) showing low median fluorescent intensity. For viruses, positive/negative percentage agreements of Seegene and Luminex were 99%/96% and 93%/99%, respectively (Yoo et al., 2019).” Overall, the authors conclude by suggesting that these assays are promising in the detection of gastrointestinal pathogens simultaneously.

Mahony and colleagues concluded that multiplex PCR-based testing was the most cost-effective strategy for the diagnosis of respiratory virus infections in children and resulted in better patient outcomes (shorter hospital stays) at lower costs (Mahony et al., 2009). Ginocchio and colleagues compared the sensitivities, specificities, positive predictive values, and negative predictive values of four different Influenza A diagnostic tests, including rapid antigen, direct immunofluorescence, viral culture, and PCR panel. The authors inferred that the PCR panel test provided the best diagnostic option with the highest sensitivity for the detection of all influenza strains and identified a significant number of additional respiratory pathogens (Ginocchio et al., 2009). Subramony and colleagues reported the use of multiplex PCR-based assays for respiratory viruses in hospitalized patients resulted in decreased healthcare resource utilization, including decreased use of antibiotics and chest radiographs (Subramony, Zachariah, Krones, Whittier, & Saiman, 2016). Babady et al. (2018) evaluated a new panel of 19 viruses and 2 bacteria (ePlex Respiratory Panel) with 2908 samples by comparing it to BioFire FilmArray. Overall agreement was >95% for all targets, and positive agreement ranged from 85.1% to 95.1%. Negative agreement ranged from 99.5% to 99.8% (Babady et al., 2018).

The Infectious Diseases Society of America (IDSA) stated that CSF RT-PCR can be one of the methods used for the diagnosis of rabies virus and enteroviral encephalitis (Tunkel et al., 2008). Several studies have evaluated the clinical impact of RT-PCR for the detection of enterovirus in the CSF of patients with aseptic meningitis (Ramers, Billman, Hartin, Ho, & Sawyer, 2000; Robinson et al., 2002; Stellrecht, Harding, Woron, Lepow, & Venezia, 2002). These studies showed a reduction in unnecessary diagnostic and therapeutic intervention (for example, antibiotic use, ancillary tests, etc.), length of hospital stay, and hospital costs. Tzanakaki and colleagues evaluated a multiplex PCR assay for detection of Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type b, and concluded that the test had high sensitivity (between 88% and 93.9%), an overall specificity and positive predictive value of 100%, and a negative predictive value >99% (Tzanakaki et al., 2005). Leber and colleagues evaluated the performance of a commercially available multiplex PCR-based panel for meningitis and encephalitis, and concluded that the test is a sensitive and specific aid in diagnosis of CNS infections and leads to improved patient outcomes (Leber et al., 2016). Another study compared the FilmArray meningitis/encephalitis (ME) panel by BioFire Diagnostics, which uses 0.2 mL of CSF to test for 14 pathogens in one hour (BioFire, 2020b), to traditional culture and PCR assay methods. The FilmArray ME panel “demonstrated an overall percent positive agreement (PPA) of 97.5% (78/80) for bacterial pathogens, 90.1% (145/161) for viruses, and 52% (26/50) for Cryptococcus neoformans/C. gattii. Despite the low overall agreement (52%) between the ME panel and antigen testing for detection of C. neoformans/C. gattii, the percent positive agreement of the FilmArray assay for C. neoformans/C. gattii was 92.3% (Liesenfeld et al., 2014; Liesman et al., 2018).”
Pathogen Panel Testing AHS – G2149

The use of multiplex PCR assays to identify pathogens following positive blood culture can be faster than standard techniques involving phenotypic identification and antimicrobial susceptibility testing that is required up to 72 hours after the blood culture became positive (Liesenfeld et al., 2014). A prospective randomized controlled trial evaluating outcomes associated with multiplex PCR detection of bacteria, fungi, and resistance genes directly from positive blood culture bottles concluded that the testing led to more judicious antibiotic use (Banerjee et al., 2015). A study by Ward and colleagues compared the accuracy and speed of organism and resistance gene identification of two commercially available multiplex-PCR sepsis panels to conventional culture-based methods for 173 positive blood cultures. The researchers discovered that both the assays accurately identified organisms and significantly reduced the time to definitive results (on average, between 27.95 and 29.17 hours earlier than conventional method) (Ward et al., 2015). Another study assessed the diagnostic accuracy of a commercially available multiplex PCR-based assay for detecting infections among patients suspected of sepsis. They concluded that the test had high specificity with a modest sensitivity and had higher rule-in value than the rule-out value. If the patient had a positive result, a clinician can confidently diagnose sepsis and begin appropriate antimicrobial therapy while avoiding unwanted additional testing (Chang et al., 2013).

An example of multiplex PCR assays can be found with two of Ubiome’s sequencing tests, SmartGut and SmartJane. Both tests use multiplex PCR to detect the presence of over 20 different microorganisms in biologically diverse environments. SmartGut measures a specimen’s gut flora (such as Dialister invisus or Lactococcus lactis) whereas SmartJane measures a specimen’s vaginal flora (such as Lactobacillus iners or Treponema pallidum). The tests propose that they can provide a health snapshot of the environment tested based on the levels of microorganisms detected. The procedures for each test are similar; both require the user to self-sample (a stool sample for SmartGut and a swab inside the vagina for SmartJane) and send the sample back to Ubiome where it is analyzed by their labs. The labs use Precision Sequencing technology to extract DNA from the microorganisms in the sample and Illumina Next-Generation to sequence the targeted genes. Then, phylogenetic algorithms are used to analyze and organize the DNA from those microorganisms. Finally, a clinical report detailing the levels of the targeted microorganisms is sent to the user and medical provider (Ubiome, 2018a). The report contains measurements of its targeted microorganisms, whether those measurements are within the normal reference ranges for certain conditions, and whether certain high danger pathogens are present (such as C. difficile for SmartGut or Chlamydia trachomatis for SmartJane). SmartJane also tests for 19 different HPV strains (Ubiome, 2018b, 2018c). Ubiome claims an average of 99% sensitivity and 100% specificity on the species-level targets for SmartGut and 97.4% sensitivity and 100% specificity for its genus-level targets, but no independent studies were found to support those claims (Ubiome, 2018a). However, these tests have since been discontinued.

There are a few limitations with this type of testing. First, the level, detection or non-detection, of a microorganism does not necessarily imply a diagnosis. The tests can only describe the levels of microorganisms found in the environment, but additional information is required to make a diagnosis. Second, the scope of the 16S rRNA sequencing used in testing such as SmartGut and SmartJane may be limited. Differences in regions more specific than rRNA (such as surface antigens or individual toxin genes) cannot be resolved with this test. For example, the test cannot distinguish between a pathogenic C. difficile strain and a nonpathogenic one. Moreover, the tests report some of their targets at a genus level only, which means that these targets cannot be differentiated at the species level (Almonacid et al., 2017; Watts et al., 2017). Finally, the PCR technique can introduce errors during the amplification leading to incorrect detection. PCR enzymes may accidentally create “artefacts” or otherwise incorrect sequences causing the detection or measurement of the microorganisms to be inaccurate (V. Wintzingerode, Göbel, & Stackebrandt, 1997).

UroSwab is a urine-based proprietary test from Medical Diagnostics LLC. UroSwab is a real-time PCR test intended to detect numerous pathogens—53 different targets as of April 2019—potentially involved in sexually transmitted and urological infections. This test uses a patient’s urine, and the turnaround time is estimated at 24-72 hours. The results include whether a pathogen’s presence was
normal or abnormal and includes comments on what the pathogen’s presence means (Diagnostics, 2015a, 2015b).

Guidelines and Recommendations

American College of Gastroenterology (ACG) (Riddle et al., 2016; Surawicz et al., 2013)

American College of Gastroenterology stated that “diarrheal disease by definition has a broad range of potential pathogens particularly well suited for multiplex molecular testing. Several well-designed studies show that molecular testing now surpasses all other approaches for the routine diagnosis of diarrhea. Molecular diagnostic tests can provide a more comprehensive assessment of disease etiology by increasing the diagnostic yield compared with conventional diagnostic tests (Riddle et al., 2016).” Furthermore, the ACG recommended that “traditional methods of diagnosis (bacterial culture, microscopy with and without special stains and immunofluorescence, and antigen testing) fail to reveal the etiology of the majority of cases of acute diarrheal infection. If available, the use of Food and Drug Administration-approved culture independent methods of diagnosis can be recommended at least as an adjunct to traditional methods. (Strong recommendation, low level of evidence).”

The ACG also notes:

- “Diagnostic evaluation using stool culture and culture-independent methods if available should be used in situations where the individual patient is at high risk of spreading disease to others, and during known or suspected outbreaks”.

- “Stool diagnostic studies may be used if available in cases of dysentery, moderate–severe disease, and symptoms lasting >7 days to clarify the etiology of the patient’s illness and enable specific directed therapy” (Riddle et al., 2016).

In 2013, the ACG made the following recommendations on diagnostic tests used for Clostridiu
m
difficile infections (Surawicz, et al, 2013):

- “Only stools from patients with diarrhea should be tested for Clostridium difficile. (Strong recommendation, high-quality evidence)”

- “Nucleic acid amplification tests (NAAT) for C. difficile toxin genes such as PCR are superior to toxins A + B EIA testing as a standard diagnostic test for CDI. (Strong recommendation, moderate-quality evidence)”

- “Glutamate dehydrogenase (GDH) screening tests for C difficile can be used in two- or three-step screening algorithms with subsequent toxin A and B EIA testing, but the sensitivity of such strategies is lower than NAATs. (Strong recommendation, moderate-quality evidence)”

- “Repeat testing should be discouraged. (Strong recommendation, moderate-quality evidence)”

- “Testing for cure should not be done. (Strong recommendation, moderate-quality evidence)”

World Gastroenterology Organization (Farthing et al., 2013)

The World Gastroenterology Organization guidelines (Farthing et al., 2013) on acute diarrhea in adults and children have no recommendations for multiplex PCR testing.

Infectious Diseases Society of America (IDSA) (Caliendo et al., 2013; Miller et al., 2018; Shane et al., 2017; Uyeki et al., 2018)
Pathogen Panel Testing AHS – G2149

In 2013, the IDSA stated that “molecular diagnostics that detect microbial DNA directly in blood have achieved a modest level of success, but several limitations still exist. Based on available data, well-designed multiplex PCRs appear to have value as sepsis diagnostics when used in conjunction with conventional culture and routine antibiotic susceptibility testing” (Caliendo et al., 2013).

The IDSA published guidelines for the diagnosis and management of infectious diarrhea which state:

Stool testing should be performed for Salmonella, Shigella, Campylobacter, Yersinia, C. difficile, and STEC in people with diarrhea accompanied by fever, bloody or mucoid stools, severe abdominal cramping or tenderness, or signs of sepsis. However, other bacterial, viral, and parasitic agents should be considered regardless of symptoms. Any specimen testing positive for bacterial pathogens by culture independent diagnostics (such as an antigen based molecular assay) should be cultured in a clinical or public health laboratory if isolation was requested or required. Finally, clinical consideration should occur with interpretation of results of multi-pathogen NAATs as these tests only detect DNA and not necessarily pathogens (Shane et al., 2017).

The IDSA acknowledges the availability of an FDA-approved multiplex PCR targeting 14 organisms for diagnosing encephalitis and meningitis, but the society states it “should not be considered a replacement for culture.” The IDSA also notes that for gram-negative or gram-positive bacteria, bacterial culture is noted as the main diagnostic procedure (albeit at low sensitivity and optional). Regarding UTI, the IDSA only recommends nucleic acid testing for adenovirus and BK polyoma virus (Miller et al., 2018).

Regarding “wounds” (termed skin and soft tissue infections in the IDSA guideline), the IDSA typically recommends culture for most pathogens. Only a few strains of bacteria and viruses (such as Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus spp, MRSA, and streptococci) were recommended for nucleic acid testing with the majority of bacterial and fungal pathogens recommended for culture instead (Miller et al., 2018).

The IDSA recommends RT-PCR or other molecular tests over other influenza tests in hospitalized patients. RT-PCR tests targeting a panel of respiratory pathogens are recommended in hospitalized, immunocompromised patients (Uyeki et al., 2018).


A Global Wound Biofilm Expert Panel have strongly agreed that “there are currently no routine diagnostic tests available to confirm biofilm presence” and that “the most important measure for future diagnostic tests to consider is indication of where the biofilm is located within the wound (Schultz et al., 2017).”

Society of Critical Care Medicine and the European Society of Intensive Care Medicine (Rhodes et al., 2017)

A joint collaboration of the Society of Critical Care Medicine and the European Society of Intensive Care Medicine issued international guidelines for management of sepsis and septic shock. It states “in the near future, molecular diagnostic methods may offer the potential to diagnose infections more quickly and more accurately than current techniques. However, varying technologies have been described, clinical experience remains limited, and additional validation is needed before recommending these methods as an adjunct to or replacement for standard blood culture techniques (Rhodes et al., 2017).”

A 2020 update regarding “Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children” was published by the Society of Critical Care Medicine (SCCM), European Society of Intensive Care Medicine (ESICM), and the International Sepsis Forum. In it, they acknowledge the presence of new molecular technologies, but remark that they are “currently relatively expensive,
are not sufficient for all pathogens and antibiotic sensitivities, and are not universally available” (Weiss et al., 2020).

**National Institute for Health and Care Excellence (NICE) (NICE, 2017)**

NICE states there is “insufficient evidence to recommend the routine adoption in the NHS of the integrated multiplex polymerase chain reaction tests, xTAG Gastrointestinal Pathogen Panel, FilmArray GI Panel and Faecal Pathogens B assay, for identifying gastrointestinal pathogens in people with suspected gastroenteritis”. NICE acknowledges that the tests show promise but need further data on their clinical utility (NICE, 2017).

**American Society for Microbiology/Association for Molecular Pathology/Association of Public Health Laboratories/College of American Pathologists/Infectious Diseases Society of America/Pan American Society for Clinical Virology (Microbiology, 2017)**

These societies made a joint statement regarding respiratory viral panels and noted three populations in which multiplex panels would be beneficial. Those populations were “immunocompromised hosts, adult patients appearing acutely ill who are potential hospital admissions, and critically-ill adult patients, particularly ICU patients” (Microbiology, 2017).

**The European Association of Urology (EAU) (Bonkat et al., 2020)**

The EAU published guidelines on UTIs in 2020. For uncomplicated UTIs (recurrent UTIs, cystitis, pyelonephritis), the EAU does not mention molecular testing at any point of the treatment algorithm; instead, they recommend bacterial culture or dipstick testing for diagnosis and recommending against extensive workup. The EAU notes that antimicrobial susceptibility testing should be performed, but their guidelines do not suggest any methods over another. In complicated UTIs, the EAU recommends urine culture to identify particular strains of bacteria (Bonkat et al., 2020).

**American College of Chest Physicians (CHEST) (Hill et al., 2019)**

The CHEST have recommended that outpatient adults with an acute cough and suspected pneumonia should not undergo routine microbiological testing because there is no need for such testing. However, testing may be considered if the results would change the therapeutic approach. Microbiological tests may include culture, serologic, and PCR testing (Hill et al., 2019).

**Centers for Disease Control and Prevention (CDC) (CDC, 2020)**

Regarding molecular tests that are commonly used for a *C. difficile* diagnosis, the (CDC, 2020) states that “FDA-approved PCR assays, which test for the gene encoding toxin B, are same-day tests that are highly sensitive and specific for the presence of a toxin-producing *C. diff* organism. Molecular assays can be positive for *C. diff* in individuals who are asymptomatic. When using multi-pathogen (multiplex) molecular methods, the results should be read with caution. In addition, patients with other causes of diarrhea might be positive, which could lead to over-diagnosis and treatment.”

**Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) (McDonald et al., 2018)**

The IDSA and SHEA have stated that the best-performing method for detecting patients with a greater risk of a *C. difficile* infection from a stool sample is to “Use a stool toxin test as part of a multistep algorithm (ie, glutamate dehydrogenase [GDH] plus toxin; GDH plus toxin, arbitrated by nucleic acid amplification test [NAAT]; or NAAT plus toxin) rather than a NAAT alone for all specimens received in the clinical laboratory when there are no preagreed institutional criteria for
Pathogen Panel Testing AHS – G2149

patient stool submission (Figure 2) (weak recommendation, low quality of evidence) (McDonald et al., 2018).” These guidelines also state that repeat testing (within 7 days) should not be performed. Panel testing is not specifically mentioned in these guidelines.

American Society of Transplantation Infectious Diseases Community of Practice (La Hoz & Morris, 2019)

These guidelines focus on identifying infections in transplant patients. Their recommendations are as follows:

“For the diagnosis of SOT [solid organ transplant] recipients with suspected gastrointestinal infections”, gastrointestinal multiplex molecular assays are recommended to identify Cryptosporidium, Cyclospora, and Giardia (La Hoz & Morris, 2019).

American Society for Clinical Pathology (ASCP, through ChoosingWisely) (ASCP, 2019a, 2019b)

The ASCP states “Do not routinely order broad respiratory pathogen panels unless the result will affect patient management.” They further state that patient management may include “provid [ing] immediate diagnosis and potentially expedite management decisions” and list “rapid molecular or point of care tests for RSV, Influenza A/B, or Group A pharyngitis” as examples (ASCP, 2019a).

The ASCP recommends against testing “for community gastrointestinal stool pathogens in hospitalized patients who develop diarrhea after day 3 of hospitalization” and instead recommend considering testing for C. difficile (ASCP, 2019b).

Applicable Federal Regulations

A search of the FDA database on 04/16/2020 using the term “pathogen panel” yielded 15 results, the term “respiratory panel” yielded 23 results, the term “blood culture panel” yielded 9 results, the term “meningitis panel” yielded 1 result, and the term “gastrointestinal panel” yielded 13 results. Thirteen of these tests were approved in 2019. Descriptions of some of these tests are shown below. Additional tests may be considered laboratory developed tests (LDTs); developed, validated and performed by individual laboratories. LDTs are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA’88). As an LDT, the U. S. Food and Drug Administration has not approved or cleared this test: however, FDA clearance or approval is not currently required for clinical use.

All of the below descriptions are taken from the FDA website.

Respiratory Pathogen Panels

On January 10, 2011 the FDA approved the Verigene® Respiratory Virus Plus Nucleic Acid Test (RV+) on the Verigene® System as a qualitative nucleic acid multiplex test intended to simultaneously detect and identify multiple respiratory virus nucleic acids in nasopharyngeal (NP) swab specimens from individuals with signs and symptoms of respiratory tract infection.

On February 17, 2012 the FDA approved the xTAG® Respiratory Viral Panel (RVP) as a qualitative nucleic acid multiplex test intended for the simultaneous detection and identification of multiple respiratory virus nucleic acids in nasopharyngeal swabs from individuals suspected of respiratory tract infections.

On September 10, 2012 the eSensor Respiratory Viral Panel (RVP) was approved as a qualitative nucleic acid multiplex in vitro diagnostic test intended for use on the eSensor XT-8 system for the simultaneous detection and identification of multiple respiratory viral nucleic
An Independent Licensee of the Blue Cross and Blue Shield Association

Pathogen Panel Testing AHS – G2149

acids in nasopharyngeal swabs (NPS) obtained from individuals exhibiting signs and symptoms of respiratory infection.

On December 17, 2015 the FDA approved NxTAG® Respiratory Pathogen Panel as a qualitative test intended for use on the Luminex® MAGPIX® Instrument for the simultaneous detection and identification of nucleic acids from multiple respiratory viruses and bacteria extracted from nasopharyngeal swabs collected from individuals with clinical signs and symptoms of a respiratory tract infection.

On May 30, 2017 the FilmArray® Respiratory Panel 2 (RP2) is a multiplexed nucleic acid test intended for use with FilmArray® 2.0 or FilmArray® Torch systems for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of respiratory tract infections.

On June 9, 2017 the FDA approved the EPlex Respiratory Pathogen Panel as a multiplexed nucleic acid in vitro diagnostic test intended for use on the ePlex® Instrument for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals exhibiting signs and symptoms of respiratory tract infection.

On August 30, 2017 the FDA approved the Idylla Respiratory (IFV-RSV) Panel is an in vitro assay intended for the qualitative detection of nucleic acids for Influenza A, Influenza A subtype H1, Influenza A subtype H3, Influenza A subtype 2009 H1, H275Y mutation of Influenza A subtype 2009 H1, Influenza B and Respiratory Syncytial Virus (A and B) from nasopharyngeal swabs in viral transport media of adult and pediatric patients. The test uses the Idylla system to aid in the diagnosis of respiratory viral infection when used in conjunction with other clinical and laboratory findings.

Blood Culture Pathogen Panels

On January 30, 2015 the FDA approved FilmArray Blood Culture Identification (BCID) Panel for use with the FilmArray 2.0.

On March 25, 2016 the FDA approved the Great Basin Staph ID/R Blood Culture Panel is a qualitative, multiplex, nucleic acid-based in vitro diagnostic assay intended for the simultaneous identification of nucleic acid from Staphylococcus aureus, Staphylococcus lugdunensis and various Staphylococcus species to the genus level and the detection of the mecA gene for methicillin resistance directly from patient positive blood culture specimens.

On June 22, 2017 the FDA approved FilmArray NGDS Warrior Panel.

Meningitis Pathogen Panels

On October 8, 2015 the FDA approved the FilmArray Meningitis/Encephalitis (ME) Panel as a qualitative multiplexed nucleic acid-based in vitro diagnostic test intended for use with FilmArray and FilmArray 2.0 systems. The FilmArray ME Panel is capable of simultaneous detection and identification of multiple bacterial, viral, and yeast nucleic acids directly from cerebrospinal fluid (CSF) specimens obtained via lumbar puncture from individuals with signs and/or symptoms of meningitis and/or encephalitis.

Gastrointestinal Pathogen Panels

On January 16, 2013 the FDA approved the Prodesse® ProGastro SSCS Assay as a multiplex real time PCR in vitro diagnostic test for the qualitative detection and differentiation of Salmonella, Shigella, and Campylobacter (C. jejuni and C. coli only, undifferentiated) nucleic acids and Shiga Toxin 1 (stx1) and Shiga Toxin 2 (stx2) genes. Shiga toxin producing E. coli (STEC) typically
Pathogen Panel Testing AHS – G2149

harbor one or both genes that encode for Shiga Toxins 1 and 2. Nucleic acids are isolated and purified from preserved stool specimens obtained from symptomatic patients exhibiting signs and symptoms of gastroenteritis.

On March 21, 2013 the FDA approved the xTAG® Gastrointestinal Pathogen Panel (GPP) as a multiplexed nucleic acid test intended for the simultaneous qualitative detection and identification of multiple viral, parasitic, and bacterial nucleic acids in human stool specimens from individuals with signs and symptoms of infectious colitis or gastroenteritis.

On May 2, 2014 the FDA approved the FilmArray Gastrointestinal (GI) Panel as a qualitative multiplexed nucleic acid-based in vitro diagnostic test intended for use with the FilmArray Instrument. The FilmArray GI Panel is capable of the simultaneous detection and identification of nucleic acids from multiple bacteria, viruses, and parasites directly from stool samples in Cary Blair transport media obtained from individuals with signs and/or symptoms of gastrointestinal infection.

On June 20, 2014 the FDA approved the Verigene Enteric Pathogens Nucleic Acid Test (EP) as a multiplexed, qualitative test for simultaneous detection and identification of common pathogenic enteric bacteria and genetic virulence markers from liquid or soft stool preserved in Cary-Blair media, collected from individuals with signs and symptoms of gastrointestinal infection.

On September 16, 2014 the FDA approved the e xTAG® Gastrointestinal Pathogen Panel (GPP) as a multiplexed nucleic acid test intended for the simultaneous qualitative detection and identification of multiple viral, bacterial and parasitic nucleic acids in human stool specimens or human stool in Cary Blair media from individuals with signs and symptoms of infectious colitis or gastroenteritis.

On May 2, 2017 the FDA approved the BD MAX Extended Enteric Bacterial Panel performed on the BD MAX System, as an automated in vitro diagnostic test for the direct qualitative detection and differentiation of enteric bacterial pathogens.

On July 12, 2017 the FDA approved the Great Basin Stool Bacterial Pathogens Panel is a multiplexed, qualitative test for the detection and identification of DNA targets of enteric bacterial pathogens. The Stool Bacterial Pathogens Panel is performed directly from Cary Blair or C&S Medium preserved stool specimens from symptomatic patients with suspected acute gastroenteritis, enteritis, or colitis and is performed on the Portrait™ Analyzer.

On November 29, 2018, the FDA approved the BD Max Enteric Viral Panel for use as an in vitro diagnostic test to detect and differentiate enteric viral pathogens, including Norovirus, Rotavirus, Adenovirus, Sapovirus, and human Astrovirus.

Billing/Coding/Physician Documentation Information

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.


BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.
Scientific Background and Reference Sources


ASCP. (2019a). Do not routinely order broad respiratory pathogen panels unless the result will affect patient management. . Retrieved from https://www.choosingwisely.org/clinician-lists/ascp-broad-respiratory-pathogen-panels/


Pathogen Panel Testing AHS – G2149


Pathogen Panel Testing AHS – G2149


Luminex. (2020b). xTAG® Gastrointestinal Pathogen Panel (GPP). Retrieved from https://www.luminexcorp.com/gastrointestinal-pathogen-panel/?gclid=Cj0KCQiAm4TyBRDgARlsAOU75sq8v_n4U520TeNwjTGoF0Lw6KT8Bk40NSIXB_H4b98iTTrfEl8bVicaAqF-EALw_wcB


Pathogen Panel Testing AHS – G2149


Pathogen Panel Testing AHS – G2149


Pathogen Panel Testing AHS – G2149


Policy Implementation/Update Information

1/1/2019 New policy developed. BCBSNC will provide coverage for Multiplex PCR-based panel testing when it is considered to be medically necessary because criteria and guidelines are met. Medical Director review 1/1/2019. Policy noticed 1/1/2019 for effective date 4/1/2019.

4/16/2019 Removed item B that concerns “travel-related diarrhea” from the When Covered section and added second paragraph stating that genetic panel sequencing testing methods such as SmartGut™ and SmartJane™ to identify microbes is investigational to the When Not Covered section. Updated policy guidelines and references. Medical Director review 4/2019. (jd)

10/1/2019 Reviewed by Avalon 2nd Quarter 2019 CAB. Related Policies added to Description section. Revised the indications under the When Not Covered section to include the nature of the sample as well as UroSwab®. The following codes were added to the Billing/Coding section: 0068U, 0086U, 0097U, 0098U, 0099U, 0100U, and code table removed. References updated. Medical Director review 8/2019. (jd)

10/29/19 Wording in the Policy, When Covered, and/or Not Covered section(s) changed from Medical Necessity to Reimbursement language, where needed. (gm)

2/11/20 Annual review by Avalon 4th Quarter 2019 CAB. Added items 2 and 3 to the When Not Covered section. Billing/Coding section: added the following codes 0107U, 0112U, 0140U, 0141U, 0142U, 0151U, 0152U. Medical Director review 12/2019. (jd)
Pathogen Panel Testing AHS – G2149


5/12/20  Reviewed by Avalon 1st Quarter 2020 CAB. Related Policies section updated, added Diagnosis Of Vaginitis Including Multi-Target PCR Testing AHS – M2057 and Onychomycosis Testing AHS – M2172. Revised the When Covered section as follows: item #1: revised reimbursement statement and added “(GIP) up to 5 pathogens”, along with “*(See Note 1)”; item #2: added “In the outpatient setting before the reimbursement statement, along with “gastrointestinal”, “up to 11 pathogens”, “immunosuppressed or HIV positive patients AND any of the following situations *(See Note 1)” along with corresponding criteria noted in items a. and b. Revised item #3 to allow for “up to 5 respiratory pathogens”, added “Note 1”. Revised the When Not Covered section as follows: added items 1-4. Policy guidelines and references updated. Removed codes 87150, 87486, 87496, 87498, 87529, 87532, 87581, 87634, 87653, 87798 and 0107U. Added CPT codes 87631 and 87632. Medical Director reviewed 4/2020. (jd)

7/28/20  Reviewed by Avalon 2nd Quarter 2020 CAB. Note added to the policy statement as follows: “The coverage criteria outlined in this policy are not applicable to diagnostic COVID-19 testing.” Policy guidelines and references updated. The following codes were added to the Billing/Coding section: 87631, 87632. Medical Director review 7/2020. (jd)

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.